A cuboid zeolitic imidazolate framework-8 nanoparticle and a preparation method and application thereof

By preparing cuboid-shaped zeolite imidazole ester framework-8 nanoparticles as adjuvants, the problem of insufficient immunogenicity of inactivated vaccines and subunit vaccines was solved, achieving potent immune response activation and antigen retention in nasal mucosal vaccines, with good biocompatibility and stability.

CN120535766BActive Publication Date: 2025-12-09HENAN AGRICULTURAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202510762897.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-06-09
Publication Date
2025-12-09
Estimated Expiration
2045-06-09

AI Technical Summary

Technical Problem

Existing inactivated and subunit vaccines have limited immunogenicity and are difficult to induce a strong immune response, requiring adjuvants to enhance the body's immune response.

Method used

Using cuboid zeolite imidazole ester framework-8 nanoparticles (cZIF-8) as adjuvants, mesoporous or narrow-pore structured nanoparticles with uniformly distributed carbon, oxygen, zinc, nitrogen, and manganese elements are prepared and used in nasal mucosal vaccines to enhance antigen presentation and mucosal immune activation.

Benefits of technology

cZIF-8 nanoparticles significantly improved antigen retention time and immune response intensity in the nasal mucosa, enhanced Th1 and Th2 immune responses, increased the activation level of CD4+ and CD8+ T cells, and exhibited good biocompatibility and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005440752960000091
    Figure BDA0005440752960000091
  • Figure HDA0005440752970000011
    Figure HDA0005440752970000011
  • Figure HDA0005440752970000021
    Figure HDA0005440752970000021
Patent Text Reader

Abstract

The application provides a cuboid-shaped zeolitic imidazolate framework-8 nanoparticle, which comprises elements of carbon (C), oxygen (O), zinc (Zn), nitrogen (N) and manganese (Mn); and is a cuboid-shaped ZIF-8 nanoparticle with a mesoporous or microporous structure, a length-diameter ratio of (1-5):1, and elements of carbon (C), oxygen (O), zinc (Zn), nitrogen (N) and manganese (Mn) uniformly distributed in the cuboid-shaped ZIF-8 nanoparticle; and the cuboid-shaped ZIF-8 nanoparticle has good adjuvant activity. Meanwhile, the application also provides a preparation method and application of the cuboid-shaped zeolitic imidazolate framework-8 nanoparticle.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application relates to the field of biological medicine, in particular to a cuboid zeolitic imidazolate framework-8 nanoparticle and a preparation method and application thereof. BACKGROUND

[0002] Adjuvant is an important component in vaccine development, which can significantly enhance the immunogenicity of vaccines, mainly used in inactivated vaccines and subunit vaccines. Inactivated vaccines are vaccines prepared by inactivating pathogens, with relatively complete antigen components but loss of antigen activity, while subunit vaccines are vaccines prepared using specific antigen proteins of pathogens. The immunogenicity of these two vaccines is relatively limited, and it is difficult to induce a strong immune response when used alone. The addition of adjuvant can stimulate the immune system of the body, improve the recognition and response of the body to vaccine antigens, enhance the production of antibodies and the activation of immune cells, prolong the duration of immune response, and thus improve the protective effect of vaccines.

[0003] Metal organic framework (MOF) is an extended network structure with high porosity formed by coordination of metal ions or nodes and organic linker molecules. The strong coordination bond between metal nodes or clusters and ligands is the source of establishing rigidity and guiding the well-defined geometry within this material. So far, the main source of variation in MOF array structure is the difference between the secondary building units that form metal ion clusters and the organic linkers that connect these clusters. Coordination number represents the number of linkers coordinated to each cluster, which can be as high as 66. Among all these geometric variants, metals of similar valence can be substituted for each other. MOFs have excellent performance (e.g., large specific surface area, high porosity, tunable chemical composition and structure, and rich functional properties), and different types of functional groups can be introduced through post-modification methods for targeted performance regulation, preparing MOFs materials for different target applications, thus showing great application potential in gas storage, sensing, drug delivery, and vaccine development. SUMMARY

[0004] The purpose of the present application is to overcome the deficiencies of the prior art, and to provide a cuboid zeolitic imidazolate framework-8 nanoparticle (cZIF-8). Secondly, the present application provides a preparation method of the cuboid ZIF-8 nanoparticle. Thirdly, the present application provides a novel application of the cuboid ZIF-8 nanoparticle as an adjuvant, and further provides an application in the preparation of prophylactic biological products and / or immunotherapeutic drugs.

[0005] To achieve the above purpose, the technical scheme adopted by the present application is:

[0006] A cuboid-shaped zeolitic imidazolate framework-8 nanoparticle, which mainly comprises elements carbon (C), oxygen (O), zinc (Zn), nitrogen (N) and manganese (Mn); and is a cuboid-shaped ZIF-8 nanoparticle with a mesoporous or narrow pore structure, an aspect ratio of (1-5):1, and elements carbon (C), oxygen (O), zinc (Zn), nitrogen (N) and manganese (Mn) uniformly distributed in the cuboid-shaped ZIF-8 nanoparticle.

[0007] A preparation method of the cuboid-shaped zeolitic imidazolate framework-8 nanoparticle, comprising the following steps: dissolving 70-350 parts by mass of a soluble manganese salt in an organic solvent; then adding 150 parts by mass of spherical ZIF-8 nanoparticles, and oscillating the reaction at room temperature; centrifuging to obtain a solid material; adding the solid material into a mixed solution of 2,5-dihydroxyterephthalic acid and an organic solvent, and oscillating the reaction at room temperature; and centrifuging and drying to obtain the cuboid-shaped ZIF-8 nanoparticle.

[0008] The first oscillation reaction is performed for 1-3 hours, and the second oscillation reaction is performed for 20-30 hours.

[0009] The soluble manganese salt is manganese chloride tetrahydrate, manganese sulfate or manganese nitrate.

[0010] The organic solvent is N,N-dimethylformamide, anhydrous ethanol or methanol.

[0011] The spherical ZIF-8 nanoparticles can be purchased or prepared by oneself.

[0012] A preparation method of the spherical ZIF-8 nanoparticles comprises: dissolving a soluble zinc salt in deionized water to obtain solution A; dissolving 2-methylimidazole in deionized water to obtain solution B; mixing and reacting solution A and solution B, centrifuging, washing and drying to obtain the spherical ZIF-8 nanoparticles.

[0013] The molar ratio of the soluble zinc salt to 2-methylimidazole is 1:(2-4).

[0014] The soluble zinc salt is zinc acetate dihydrate, zinc nitrate hexahydrate, zinc chloride or zinc sulfate; and the deionized water has a resistivity of no less than 18.2 MΩ / cm.

[0015] The cuboid-shaped zeolitic imidazolate framework-8 nanoparticle as an adjuvant.

[0016] The adjuvant is applied to the preparation of prophylactic biological products or immunotherapeutic drugs, and is particularly suitable for application in the preparation of nasal mucosa vaccines.

[0017] The application has outstanding substantial features and significant progress compared with the prior art, in particular, the application provides a cuboid-shaped zeolitic imidazolate framework-8 nanoparticle, the cuboid-shaped crystal structure of which is mainly composed of carbon, oxygen, zinc, nitrogen and manganese elements, the specific surface area of which is 4.3749 m 2 g -1 , which is 6.5 times of that of sZIF-8 (0.6694 m 2 g -1 ).

[0018] In terms of biological safety evaluation, after the mice are immunized by nose drops of the cZIF-8 nano adjuvant, the physiological state of the mice is normal, the weight growth curve has no statistical difference with that of the control group, and no abnormality is found in the histopathological sections of the organs and tissues, the retention time of the loaded antigen in the nasal mucosa can reach 72 h, which is significantly better than that of the sZIF-8 particle dosage form group, and the immunization effect is best when the adjuvant dosage is 1 mg.

[0019] In the research on the immunological activity of the nasal mucosa, the cZIF-8@OVA complex vaccine can significantly improve the OVA-specific IgG / IgA antibody level in the serum of the mice, improve the expression level of various cytokines and chemotactic factors, has the potential in enhancing the Th1 and Th2 type immune responses, can also up-regulate the expression level of the BMDC costimulatory molecules CD80 / CD86, promote the lysosome escape of the antigen to improve the cross-presentation efficiency, and significantly improve the activation level of the CD4 + and CD8 + T cells of the mice.

[0020] In summary, the cZIF-8 nano adjuvant can significantly enhance the antigen presentation and the activation of the mucosal immunity due to the unique structure and performance, is better than the sZIF-8 particle and the aluminum adjuvant in the humoral immunity and cellular immunity, and has good stability and biocompatibility and the long-time retention property in the nasal cavity, has obvious advantages and broad prospects in the development of the nasal mucosal vaccine.

[0021] Meanwhile, the application also provides a method for synthesizing the cZIF-8 nanoparticle by the seed-mediated growth method, which is simple, easy to operate and suitable for industrial production. BRIEF DESCRIPTION OF DRAWINGS

[0022] Figure 1-1 TEM, EDS and SEM images of sZIF-8. In the figure, A: STEM image of sZIF-8 bright field; B: HAADF-STEM image of sZIF-8; C-H: EDS images of carbon element, nitrogen element, oxygen element and zinc element of sZIF-8; I-J: SEM images of sZIF-8.

[0023] Figure 1-2TEM, EDS and SEM images of cZIF-8. In the figure, A: STEM image of cZIF-8 bright field; B: HAADF-STEM image of cZIF-8; C-H: EDS maps of carbon element, nitrogen element, oxygen element, zinc element and manganese element of cZIF-8; I-J: SEM images of cZIF-8.

[0024] Figure 1-3 XRD patterns of cZIF-8 and sZIF-8.

[0025] Figure 1-4 Fourier transform infrared spectra of cZIF-8 and sZIF-8.

[0026] Figure 1-5 XPS analysis of cZIF-8 and sZIF-8. In the figure, A: XPS scanning analysis of cZIF-8 and sZIF-8; B: high-resolution XPS analysis of Zn 2p of cZIF-8 and sZIF-8; C: high-resolution XPS analysis of Mn 2p of cZIF-8 and sZIF-8.

[0027] Figure 1-6 Surface area and pore size distribution of cZIF-8 and sZIF-8.

[0028] A: surface area of cZIF-8 and sZIF-8; B: pore size distribution of cZIF-8 and sZIF-8.

[0029] Figure 1-7 SDS-PAGE results of cZIF-8 and sZIF-8 loaded with OVA. In the figure, lane 1 is chicken ovalbumin (OVA) solution (1 mg / mL) before adsorption, lane 2 is supernatant after OVA protein solution is incubated with cZIF-8, and lane 3 is supernatant after OVA protein solution is incubated with sZIF-8.

[0030] Figure 1-8 Zeta potential analysis of cZIF-8, sZIF-8 and cZIF-8@OVA.

[0031] Figure 1-9 Figure 1-1 G and Figure 1-2 H are magnified images.

[0032] Figure 2-1 Body weight changes of mice.

[0033] Figure 2-2 H&E staining of main organ sections of mice.

[0034] Figure 2-3 In vivo fluorescence imaging of mice in different adjuvant groups.​

[0035] Figure 2-4 IgG, IgA detection results after different dose cZIF-8@OVA nasal immunization of mice. In the figure, A: IgG detection results after different dose cZIF-8@OVA nasal immunization of mice; B: IgA detection results after different dose cZIF-8@OVA nasal immunization of mice.

[0036] Figure 3-1 IgG, IgA detection results after different adjuvant mixed OVA nasal immunization of mice. In the figure, A: IgG detection results after different adjuvant mixed OVA nasal immunization of mice; B: IgA detection results after different adjuvant mixed OVA nasal immunization of mice.

[0037] Figure 3-2 OVA specific antibody titer detection. In the figure, A: IgG titer detection of each group in the 5th week serum; B: IgA titer detection of each group in the 5th week serum; C: IgG1 titer detection of each group in the 5th week serum; D: IgG2a titer detection of each group in the 5th week serum.

[0038] Figure 3-3 Each group of cytokine content detection in the 5th week serum. In the figure, A-D are in turn IL-4, IL-12, IL-17A, IFN-γ content detection in serum.

[0039] Figure 3-4 Each group of cytokine content detection in the 5th week serum. In the figure, A-D are in turn IL-4, IL-12, IL-17A, IFN-γ content detection in serum.

[0040] Figure 3-5 Mouse myeloid dendritic cells (BMDCs) identification.

[0041] Figure 3-6 Effect of different adjuvants and OVA protein on BMDCs phenotype. In the figure, A: CD80, CD86 flow cytometry detection results of different adjuvant groups; B: corresponding columnar analysis chart.

[0042] Figure 3-7 Different adjuvants combined with OVA in BMDCs and lysosomes.

[0043] Figure 3-8 Flow cytometry detection of CD4 + , CD8 + T cell content of different adjuvant groups. In the figure, A: CD8 + T cell flow cytometry detection results of different adjuvant groups; B: corresponding columnar analysis chart; C: CD4 +T cell flow cytometry test results; D: corresponding columnar analysis chart. DETAILED DESCRIPTION

[0044] The technical solutions of the present application will be described below in conjunction with specific examples and experimental examples. However, those skilled in the art should understand that the examples are only used to illustrate the technical solutions of the present application, and should not be regarded as limiting the protection scope of the present application. Based on the following examples, all other embodiments obtained by those skilled in the art without creative labor, such as modifications, deformations or simple replacements, should belong to the protection scope of the present application.

[0045] The experimental methods used in the following examples and experimental examples are conventional methods unless otherwise specified; the raw materials, reagents, instruments, etc. used are commercially available unless otherwise specified; the terms and abbreviations involved are conventional meanings in the art, for example: cuboid zeolitic imidazolate framework-8 (cZIF-8), spherical ZIF-8 (sZIF-8), ovalbumin (OVA protein), cZIF-8 after adsorbing OVA protein (cZIF-8@OVA), sZIF-8 after adsorbing OVA protein (sZIF-8@OVA), alum (aluminum hydroxide adjuvant) after adsorbing OVA protein (Alum@OVA).

[0046] Example 1

[0047] The present embodiment provides a preparation method of cuboid zeolitic imidazolate framework-8 nanoparticles, which comprises the following steps:

[0048] (1) Preparation of spherical ZIF-8 particles: 2.2 g of 2-methylimidazole (2-MeIm) was weighed and dissolved in 300 mL of ultrapure water at room temperature, 1.9 g of Zn(CH3COO)2·2H2O was dissolved in 300 mL of ultrapure water, and the solution containing Zn 2+ was slowly added dropwise into the 2-MeIm solution while stirring, then stirred in a 25°C water bath for 24 h, after the reaction was completed, the product was collected by centrifugation (10 min, 12000 rpm, 25°C), then washed with ultrapure water three times, anhydrous ethanol three times, the precipitate was collected, dried at 50-60°C, ground after drying, and sZIF-8 was prepared.

[0049] (2) Take 150 mg of sZIF-8, dissolve 80 mg of MnCl2·4H2O in 5 mL of N, N- dimethylformamide, mix uniformly by ultrasonic, then add 150 mg of sZIF-8, place in a shaking table at 25°C for 2 h of mixing reaction, collect the product by centrifugation (10 min, 20,000 rpm, 25°C), dissolve 40 mg of 2,5-dihydroxyterephthalic acid in 5 mL of N, N-dimethylformamide, add the product collected in the previous step, place in a shaking table at 25°C for 24 h of mixing reaction, collect the product by centrifugation (10 min, 12,000 rpm, 25°C), dry at 50-60°C to obtain cZIF-8.

[0050] Example 2

[0051] The present example provides a preparation method of a rectangular zeolitic imidazolate framework-8 nanoparticle, comprising the following steps:

[0052] (1) Preparation of spherical ZIF-8 particles: at room temperature, take 2.2 g of 2-methylimidazole (2-MeIm) and dissolve in 300 mL of ultrapure water, take 2.6 g of Zn(NO3)2·6H2O and dissolve in 300 mL of ultrapure water, slowly add the solution containing Zn 2+ to the 2-MeIm solution while stirring, then stir in a 25°C water bath for 24 h, after the reaction is complete, collect the product by centrifugation (10 min, 12,000 rpm, 25°C), then wash with ultrapure water three times, wash with anhydrous ethanol three times, collect the precipitate, dry at 50-60°C, grind after drying, and obtain sZIF-8.

[0053] (2) Take 150 mg of sZIF-8, disperse 90 mg of MnSO4 in 5 mL of anhydrous ethanol, mix uniformly by ultrasonic, then add 150 mg of sZIF-8, place in a shaking table at 25°C for 2 h of mixing reaction, collect the product by centrifugation (10 min, 12,000 rpm, 25°C), dissolve 40 mg of 2,5-dihydroxyterephthalic acid in 5 mL of anhydrous ethanol, add the product collected in the previous step, place in a shaking table at 25°C for 24 h of mixing reaction, collect the product by centrifugation (10 min, 12,000 rpm, 25°C), dry at 50-60°C to obtain cZIF-8.

[0054] Example 3

[0055] The present example provides a preparation method of a rectangular zeolitic imidazolate framework-8 nanoparticle, comprising the following steps:

[0056] (1) Preparation of spherical ZIF-8 particles: 2.2 g of 2-methylimidazole (2-MeIm) was dissolved in 300 mL of ultrapure water at room temperature, 1.5 g of ZnSO4 was dissolved in 300 mL of ultrapure water, the solution containing Zn 2+ was slowly added dropwise to the 2-MeIm solution while stirring, then stirred in a 25 °C water bath for 24 h, after the reaction was completed, the product was collected by centrifugation (10 min, 12000 rpm, 25 °C), then washed with ultrapure water three times, anhydrous ethanol three times, the precipitate was collected, dried at 50-60 °C, ground after drying, and sZIF-8 was prepared.

[0057] (2) 150 mg of ground sZIF-8 was weighed, 100 mg of Mn(NO3)2 was dispersed in 5 mL of methanol, after ultrasonic mixing, 150 mg of sZIF-8 was added, and placed in a shaking bed at 25 °C for 2 h of mixing reaction, the product was collected by centrifugation (10 min, 12000 rpm, 25 °C), 60 mg of 2,5-dihydroxyterephthalic acid was dissolved in 5 mL of methanol, and the product collected in the previous step was added, and placed in a shaking bed at 25 °C for 24 h of mixing reaction, the product was collected by centrifugation (10 min, 12000 rpm, 25 °C), and dried at 50-60 °C to obtain cZIF-8.

[0058] I. Characterization of sZIF-8 and cZIF-8 nanoparticles prepared in Example 1

[0059] 1. Morphological characterization of sZIF-8 / cZIF-8 particles

[0060] A small amount of sample was placed in a 1.5 mL centrifuge tube, 100 μL of ultrapure water was added, and the sample was uniformly dispersed in the centrifuge tube by ultrasonic dispersion, 5 μL of cZIF-8 nanoparticles was taken with a pipette and added dropwise to the conductive glue, 5 μL of ethanol solution was taken and added dropwise to the sample, and the sample was uniformly dispersed on the aluminum foil, and placed in a 50 °C oven, after the solvent was volatilized, the sample-coated aluminum foil was pasted onto the conductive glue, and platinum was sprayed to increase the conductivity using an ion sputtering instrument, and the morphology of the sample was observed by scanning electron microscopy, and the results are shown in Figure 1-1 and 1-2 .

[0061] Figure 1-1 In A-B, A is a bright field STEM image of sZIF-8 nanoparticles, and B is a HAADF-STEM image of sZIF-8 nanoparticles. Figure 1-1In the CG assay, the elemental distribution of the sZIF-8 nanoparticles can be clearly observed, with red to purple representing carbon (C), nitrogen (N), oxygen (O), and zinc (Zn), respectively. These elements are uniformly distributed within the sZIF-8 particles, and the main elemental composition of the sZIF-8 nanoparticle sample includes carbon (C), oxygen (O), zinc (Zn), and nitrogen (N). Figure 1-1 H is a field emission scanning electron microscope (FE-SEM) image of sZIF-8 nanoparticles.

[0062] Depend on Figure 1-2 It can be seen that by using the seed-mediated growth method, the classical rhombic dodecahedral morphology limitation was overcome, and by precisely controlling the synthesis conditions, a rectangular ZIF-8 with the correct crystal structure (1353×649×227nm, aspect ratio = 2:1) was successfully synthesized. Figure 1-2 Images A and B show the overall morphology of cZIF-8. A is a bright-field STEM image of cZIF-8, and B is a HAADF-STEM image of cZIF-8 particles. Figure 1-2 The C and CH diagrams show the elemental distribution of cZIF-8 nanoparticles. It can be clearly seen that these elements are uniformly distributed in the cuboid particle structure. The main elemental composition of the cZIF-8 sample includes carbon (C), oxygen (O), zinc (Zn), nitrogen (N) and a small amount of manganese (Mn). Figure 1-2 The image in Figure IJ shows the FE-SEM results of cZIF-8 at different magnifications.

[0063] 2. XRD analysis of sZIF-8 / cZIF-8 particles

[0064] X-ray diffraction (XRD) patterns were used to analyze the crystal type and lattice parameters of colloidal gold on the surface of cZIF-8 nanoparticles using a D / MAX-RB X-ray diffractometer. Cu Kα rays were used for testing, λ = 1.54056, with a scan rate of 1° / min and a scan range of 10–85°. The results are as follows: Figure 1-3 As shown.

[0065] from Figure 1-3 It can be seen that XRD analysis of cZIF-8 and sZIF-8 was performed using a D / MAX-RB X-ray diffractometer. cZIF-8 and sZIF-8 have the same diffraction peaks as the simulated ZIF-8, proving that the crystal structures of sZIF-8 nanoparticles and cZIF-8 nanoparticles are basically consistent with the simulated ZIF-8 crystal structure.

[0066] 3. FTIR analysis of sZIF-8 / cZIF-8 particles

[0067] The cZIF-8 nanoparticles and sZIF-8 nanoparticles were ground, 50 mg of each was mixed with 100 mg of spectroscopically pure potassium bromide powder, and the mixed materials were uniformly placed in a mold. The materials in the mold were pressed into transparent sheets under a pressure of 4x10 4 KPa, and the surface functional groups of the cZIF-8 nanoparticles and sZIF-8 nanoparticles were analyzed using a Bruker Vertex 70 Fourier transform infrared spectrometer. The results are shown in Figure 1-4

[0068] As can be seen from Figure 1-4 , the infrared spectrum of cZIF-8 and sZIF-8 was analyzed using a Vertex 70 Fourier transform infrared spectrometer. The FTIR results further confirmed that there are various functional groups on the surface of cZIF-8 and sZIF-8. The characteristic peak positions of O-H and C-H do not change much, but the characteristic peak positions of C=C, C-N and C-H of the aromatic ring of cZIF-8 nanoparticles have obvious shifts compared with sZIF-8 nanoparticles, indicating that there is a chemical adsorption effect in the self-assembly process of the functional groups on the material surface, metal ions, nanomaterials and biomolecules, among which carboxyl, thiol and amino functional groups play a key role in the chemical adsorption process.

[0069] 4. XPS analysis of sZIF-8 / cZIF-8 particles

[0070] The cZIF-8 nanoparticle sample was characterized and analyzed using an X-ray photoelectron spectrometer (XPS). Monochromatic Al Kα rays were used as the excitation source of the X-ray photoelectron spectrometer during the test, and the charge correction was performed according to the standard peak position of carbon element (C 1s = 284.8 eV). The results are shown in Figure 1-5

[0071] As can be seen from Figure 1-5 , in order to analyze the valence state of the main elements in the ZIF-8 nanoparticles, the synthesized cuboid and sZIF-8 were subjected to XPS characterization analysis. The characteristic peaks of C1s, N1s, O 1s and Zn 2p appeared in the cZIF-8 nanoparticles and sZIF-8 nanoparticles, indicating that both materials contain these elements. The results show that there are differences in the surface chemical states of the cZIF-8 nanoparticles and sZIF-8 nanoparticles, mainly in the binding energy peak positions and relative contents of C, N, O and Mn. These differences may be related to the synthesis method and structural characteristics of the two materials.

[0072] 5. Surface area and pore size analysis of sZIF-8 / cZIF-8 particles ​​

[0073] BET (Brunauer-Emmett-Teller) is a method for determining the specific surface area of a material with a multilayer adsorption model. By measuring the adsorption amount of gas on the surface of the material at different relative pressures during the equilibrium period, linear regression fitting is performed using the BET equation to calculate the specific surface area of the nanomaterial. By measuring the adsorption and desorption isotherms of the nanomaterial at different relative pressures, the pore size distribution of the cZIF-8 nanoparticles is calculated according to the BJH (Barrett-Joyner-Halenda) equation. The specific surface area of the cZIF-8 nanoparticles is calculated using the BET formula. The relative pressure P / P 0 is the ratio of the pressure of the gas in the sample pores to the saturated vapor pressure. When P / P 0 reaches 0.995, the total pore volume of the cZIF-8 nanoparticles is estimated, and the results are shown in Figure 1-6 .

[0074] As can be seen from Figure 1-6 , the adsorption-desorption curves of cZIF-8 nanoparticles and sZIF-8 nanoparticle materials both conform to the IV-type curve with a H3-type hysteresis loop according to the International Union of Pure and Applied Chemistry (IUPAC) classification, indicating that they have mesoporous structures. Moreover, the cZIF-8 nanoparticles have a larger pore volume and a narrower pore size distribution, indicating that they have uniform microporous or narrow mesoporous structures. Both cZIF-8 nanoparticles and sZIF-8 nanoparticles exhibit high porosity characteristics, but their pore size distributions and specific surface areas differ. The uniform pore size distribution of cZIF-8 nanoparticles may make them more advantageous in specific applications, and cZIF-8 nanoparticles have the potential to be used as high-efficiency adsorbents and have the ability to load antigens.

[0075] 6. Analysis of the ability of sZIF-8 / cZIF-8 particles to load proteins

[0076] 1 mg of cZIF-8 and sZIF-8 were respectively incubated with 1 mg of OVA protein at 4°C on a shaking table for 2 h, and centrifuged at 12000 rpm for 5 min. The supernatant was collected, and 10 μL was taken for SDS-PAGE to detect the OVA protein content, and the results are shown in Figure 1-7 .

[0077] As can be seen from Figure 1-7 , more than 0.5 mg of cZIF-8 nanoparticles can completely adsorb 20 μg of OVA protein.

[0078] 7. Analysis of the Zeta potential of sZIF-8 / cZIF-8 particles

[0079] 0.2 mg of cZIF-8, sZIF-8, and cZIF-8@OVA were dissolved in 1 mL of ultrapure water, respectively. The Zeta potentials of OVA, cZIF-8, sZIF-8, and cZIF-8@OVA were measured using a Zeta potential analyzer. The results are as follows: Figure 1-8 As shown.

[0080] from Figure 1-8 It can be seen that the main component of both sZIF-8 nanoparticles and cZIF-8 nanoparticles is Zn. 2+ Both are positively charged. The potentials of sZIF-8 nanoparticles and cZIF-8 nanoparticles are 40mV and 24mV, respectively, and the potential of cZIF-8@OVA is 5mV, indicating that the positively charged cZIF-8 nanoparticles are conducive to the adsorption of negatively charged OVA.

[0081] II. Biosafety Evaluation of cZIF-8 Nanoparticles

[0082] Main reagents: CCK-8 kit was purchased from Beijing Solarbio Science & Technology Co., Ltd.; Cy5.5-NHS and fluorescein isothiocyanate (FITC) were purchased from Shanghai Aladdin Biotechnology Co., Ltd.; hematoxylin staining solution, eosin staining solution and 4% paraformaldehyde fixative were purchased from Shanghai Beyotime Biotechnology Co., Ltd.; Gibco RPMI 1640 culture medium was purchased from Thermo Fisher Scientific Co., Ltd.

[0083] 1. Assessment of physiological status in mice after immunization

[0084] Mice were immunized by intranasal administration of different adjuvants: OVA, cZIF-8@OVA, sZIF-8@OVA, and Alum@OVA. Six mice were in each group, and each mouse received 50 μL. During days 0-28 after immunization, the mice's mental status, food intake, water consumption, fecal matter, and weight changes were recorded weekly. The results are shown in Table 1 and... Figure 2-1 As shown.

[0085] From Table 1 and Figure 2-1 As can be seen, after intranasal immunization, the mice in the cZIF-8 and Alum groups showed good mental state, food and water intake, and fecal matter, with no obvious abnormalities (Table 1). In the sZIF-8 group, a few mice exhibited disordered fur, while the rest remained normal. The weight changes in the cZIF-8, Alum, and sZIF-8 groups showed similar trends, with no significant difference compared to the PBS group. Twenty-eight days after vaccination, the average weight of mice in each group increased over time.

[0086] Table 1. Physiological status of mice 0-28 days after immunization with vaccines prepared with different adjuvants.

[0087]

[0088] 2. Histological analysis of major organs of mice immunized with different adjuvants

[0089] Mice were immunized with different adjuvants OVA (cZIF-8@OVA, sZIF-8@OVA, Alum@OVA) by nasal drops, 50 μL per mouse. At 28 days after immunization, the mice were aseptically sacrificed and dissected in a clean bench. The heart, liver, spleen, lung and kidney of the mice were taken out using clean scissors and forceps for histopathological section observation. The results are shown in Figure 2-2 .

[0090] As can be seen from Figure 2-2 , by observing the section analysis, the heart, liver, spleen, lung and kidney of the mice in the cZIF-8, sZIF-8 and Alum adjuvant groups were not significantly abnormal, which was consistent with the PBS group. In summary, according to the analysis of the H&E staining results, these adjuvant groups did not cause significant adverse effects on the major organs of the mice, and therefore they can be regarded as safe adjuvants for subsequent experiments.

[0091] 3. Analysis of the sustained-release characteristics of antigens regulated by different adjuvants in the mouse nasal cavity

[0092] Different adjuvants Cy5.5-OVA, cZIF-8@Cy5.5-OVA, sZIF-8@Cy5.5-OVA, Alum@Cy5.5-OVA were used to immunize mice by nasal drops, 6 mice in each group, 50 μL of complex vaccine was dropped into the nasal cavity of each mouse. After immunization, the release rate of antigen protein in the mouse nasal cavity at different time points (3, 6, 12, 24, 48 and 72 h) was dynamically observed using small animal live imaging technology. The results are shown in Figure 2-3 .

[0093] As can be seen from Figure 2-3 , the use of live imaging technology to observe the retention of different adjuvants in the mouse nasal cavity, cZIF-8 can show a higher fluorescence signal at early time points (such as 3 h and 6 h) and can maintain the fluorescence intensity, and the fluorescence signal can still be observed at 72 h, which indicates that cZIF-8 can remain in the mouse nasal cavity for a long time. The three groups of adjuvants cZIF-8, Alum and sZIF-8 are better than the single nasal immunization of Cy5.5-OVA, especially the cZIF-8 adjuvant stays on the nasal mucosa for the longest time and has the best effect.

[0094] 4. Optimization of the immunization dose of cZIF-8 adjuvant

[0095] Select 6-8 weeks old healthy female Balb / c mice 36, randomly divided into 6 groups, 6 in each group. The immune dose of antigen OVA protein is 20 μg per mouse, and the cZIF-8 adjuvant is divided into: 0.25 mg per mouse, 0.5 mg per mouse, 1 mg per mouse, 1.5 mg per mouse, 2 mg per mouse, and set up negative control group. During the immunization period, the mice have sufficient feed and water every day, and each mouse is immunized with 50 μL of complex vaccine by nasal drops. The first immunization and booster immunization were carried out on the 1st day and the 14th day, respectively. After the first immunization, the mental state, food and water intake of each mouse were recorded every day. At 1, 2, 3, 4 and 5 weeks after the first immunization, the tail blood of all mice was collected, and the collected blood samples were placed in a constant temperature incubator at 37℃ for 30 min, 4℃ for 4 h, then centrifuged at 4000 rpm for 10 min, and the upper serum was aspirated for detection of OVA specific IgG, IgA antibody content. The results are shown in Figure 2-4 .

[0096] From Figure 2-4 it can be seen that when each mouse is 1 mg, the OVA specific IgG produced by it rises rapidly in the second week, and reaches a peak at 4 weeks, and the 1 mg adjuvant group is obviously better than other groups, IgA rises rapidly after immunization in the first week, and the nasal cavity produces mucosal immune effect, and the 1 mg adjuvant group is also obviously better than other groups. Therefore, the optimal dose of cZIF-8 adjuvant nasal immunization of piglets in this experiment is 1 mg per mouse.

[0097] Three, nasal mucosal immune activity of cZIF-8 nanoparticles

[0098] Main reagents: HRP labeled goat anti-mouse IgG antibody, HRP labeled goat anti-mouse IgA antibody, HRP labeled goat anti-mouse IgG1 antibody, HRP labeled goat anti-mouse IgG2a antibody, mouse IL-4 double antibody sandwich ELISA detection kit, mouse IL-17A double antibody sandwich ELISA detection kit, mouse IFN-γ double antibody sandwich ELISA detection kit, all purchased from Wuhan Suny Bright Bioengineering Technology Co., Ltd.; mouse IL-12 enzyme-linked immunoassay ELSIA kit; Tris tris(hydroxymethyl) aminomethane, single-component TMB color developing solution, bovine serum albumin, polylysine and sodium dodecyl sulfate SDS, all purchased from Beijing Solabio Technology Co., Ltd.; RIPA lysis buffer, PMSF (100 mM), red blood cell lysis buffer, DAPI mounting medium and Lyso Tracker Red, purchased from Shanghai Biyun Tian Biotechnology Co., Ltd.; Protein Marker and Ficoll cell separation medium, purchased from Shanghai Yixing Biological Technology Co., Ltd.; SDS-PAGE gel rapid preparation kit, purchased from Wuhan Biode Biological Engineering Co., Ltd.; DPBS, purchased from Shanghai Aibixun Biological Technology Co., Ltd.; Mouse-Reactive STING Pathway Antibody Sampler Kit, purchased from Cell Signaling; GM-CSF Protein, Mouse and IL-4 Protein, Mouse, purchased from Youningwei Biological Technology Co., Ltd.; Concanavalin A (ConA), purchased from Beijing Solabio Technology Co., Ltd.; 0.25% trypsin, purchased from Sigma-Aldrich Shanghai Trading Co., Ltd.; Gibco FBS, purchased from Thermo Fisher Scientific China Co., Ltd.; FITC anti-mouse CD3, PE anti-mouse CD4, APC anti-mouse CD8, APC anti-mouse CD11c, PE anti-mouse MHC II, PE anti-mouse CD80, PE / Cy7 anti-mouse CD86 and sheath fluid, all purchased from Biolegend Beijing Biological Technology Co., Ltd.

[0099] Immune program:

[0100] Select 6-8 weeks old healthy female Balb / c mice 32, randomly divided into 4 groups, 8 in each group. Each mouse injection antigen dose of 20 μg protein antigen OVA, cZIF-8 nanoparticle dose is 1 mg / one; sZIF-8 nanoparticle dose is 2 mg / one; Alum adjuvant dose is 200 μL / one. Ensure that each group of mice daily feed and drinking water is sufficient, on the 1st day, the 15th day, the 105th day, immunization, each mouse by the way of nasal drops 50 μL. After the first immunization, record the mental state, food and water every day. Within 1-28 weeks after the first immunization, collect all the mouse blood, put the collected mouse blood into the thermostat incubator 37℃, stand for 30 min, then put it at 4℃ for 4 h, centrifuge at 4000 rpm for 10 min, collect the supernatant in the EP tube. After 5 weeks of nasal immunization, 3 mice in each experimental group were randomly killed, the spleen was dissected aseptically, and the lymphocytes were separated for use.

[0101] 1. Dynamic monitoring of OVA-specific IgG antibody

[0102] From the first week of immunizing mice, collect mouse blood and separate mouse serum every week, and continue to monitor to the 28th week, use indirect ELISA method to detect OVA-specific IgG antibody level in serum, specific test steps are as follows: first, determine the best application concentration of horseradish peroxidase labeled antibody and the best dilution degree of mouse serum by chessboard dilution method, the pre-experiment of the present study shows that: the coating amount of antigen OVA is 800 ng / well; the blocking liquid uses 5% skim milk, the best dilution concentration of serum is 1:400; the best dilution multiple of horseradish peroxidase labeled goat anti-mouse IgG is 1:10000, the TMB developing time is 15 min, and the results are as shown in Figure 3-1 A.

[0103] 2. Dynamic monitoring of OVA-specific IgA antibody

[0104] From the first week of immunizing mice, collect mouse blood and separate mouse serum every week, and continue to monitor to the 28th week, use indirect ELISA method to detect OVA-specific IgA antibody level in serum, specific steps are as follows:

[0105] First, determine the best application concentration of horseradish peroxidase labeled antibody and the best dilution degree of mouse serum by chessboard dilution method, the pre-experiment of the present study shows that: the coating amount of OVA is 100 ng / well; use 2.5% BSA for blocking, the best dilution concentration of serum is 1:100; the best dilution multiple of horseradish peroxidase labeled goat anti-mouse IgG is 1:1000, and the results are as shown in Figure 3-1 B.

[0106] From Figure 3-1It can be seen that the OVA-specific IgG antibody of the cZIF-8 group in 3-1A is rapidly up-regulated after the 2nd week, and reaches a peak at the 5th week, and the titer of IgG rapidly increases after the 15th week of immunization, indicating that the cZIF-8@OVA complex vaccine can stimulate the mouse body to produce immune memory, and can produce a strong immune response after re-immunization. In 3-1B, the IgA titer rapidly rises after the 1st week of immunization, and remains at a relatively stable level from the 2nd to the 5th week, and the titer of IgA rapidly increases and reaches a peak after the 15th week of immunization. The effects of IgG and IgA of the cZIF-8 adjuvant are obviously better than those of the sZIF-8 adjuvant.

[0107] 3. OVA-specific antibody titer detection

[0108] The OVA-specific IgG, IgG1, and IgG2a were detected by the method established in 1 of Test 3, and the OVA-specific IgA was detected by the method established in 2 of Test 3. A negative mouse serum control was set, and the judgment standard was P / N>2 to determine positive. The results are shown in Figure 3-2 .

[0109] From Figure 3-2 It can be seen that the IgG antibody titer of the cZIF-8 adjuvant group shown in 3-2A is better than that of the Alum adjuvant group (**p<0.01), and is obviously better than that of the sZIF-8 adjuvant group and the PBS group (***p<0.001, ****p<0.0001); the IgA antibody titer of the cZIF-8 adjuvant group shown in 3-2B is basically consistent with that of the Alum adjuvant (*p<0.1), and the IgA effect of the cZIF-8 is obviously better than that of the sZIF-8 adjuvant group and the PBS group (**p<0.01, ****p<0.0001); the IgG1 and IgG2a antibody titers of the cZIF-8 adjuvant group shown in 3-2C and 3-2D are better than those of the Alum adjuvant (*p<0.1), and the IgG1 and IgG2a effects of the cZIF-8 are obviously better than those of the sZIF-8 adjuvant group and the PBS group (***p<0.001, ****p<0.0001).

[0110] 4. Detection of cytokine content in serum

[0111] The content of cytokines (IL-4, IL-12, IL-17A, and IFN-γ) was determined by a double antibody sandwich ELISA detection method, and the operation steps were performed according to the kit operation instruction. The results are shown in Figure 3-3 .

[0112] From Figure 3-3 It can be seen that the high expression of the cZIF-8 group Figure 3-3A) indicates that the adjuvant can effectively promote Th2-type immune response, which can help the production of antibodies and the regulation of allergic reactions; IL-12( Figure 3-3 B) is a Th1-type cytokine, and the high expression in the cZIF-8 group indicates that the adjuvant can enhance the cell-mediated immune response; IL-17A( Figure 3-3 C) is mainly produced by Th17 cells, and the high content in the cZIF-8 group indicates that the adjuvant can promote inflammatory response and tissue repair; IFN-γ( Figure 3-3 D) is a Th1-type immune response marker cytokine, indicating that cZIF-8 can significantly enhance the cell-mediated immune response.

[0113] 5. Detection of cytokine content in spleen cell supernatant

[0114] The spleen lymphocytes of the mice at 5 weeks after immunization were separated using Ficoll cell separation solution, and the content of IL-4, IL-12, IL-17A and IFN-γ in the spleen cell supernatant of the mice at 5 weeks after immunization was detected by ELISA double antibody sandwich kit, and the results are shown in Figure 3-4 .

[0115] From Figure 3-4 it can be seen that from Figure 3-4 A result analysis, these two cytokines are related to Th2-type immune response, and can promote the proliferation and differentiation of B cells and the production of antibodies, and the significant increase of IL-4 in the cZIF-8 group indicates that the adjuvant can effectively promote Th2-type immune response; IL-12( Figure 3-4 B) this cytokine promotes Th1-type immune response, and the high expression of these two cytokines in the cZIF-8 group confirms its effect in promoting Th1-type immune response; IL-17A( Figure 3-4 C) is mainly produced by Th17 cells and participates in inflammatory response and tissue repair; IFN-γ( Figure 3-4 D) is a key cytokine of Th1-type immune response, which plays a core role in anti-virus and anti-tumor immunity, and the almost consistent and high content of IFN-γ in the cZIF-8 group and the Alum group indicates that it has a significant effect in enhancing the cell-mediated immune response.

[0116] 6. Isolation and identification of mouse myeloid dendritic cells (BMDCs)

[0117] The density of the cultured im-DCs was diluted to 1×10 6The density of the cultured im-DCs was diluted to 1×10 Figure 3-5 / 3-6.

[0118] Figure 3-5 It can be seen that the CD11c positive rate of the marrow-derived cells on the first day of culture was only 9.13%, while the CD11c positive rate after in vitro induction and culture for seven days was 58.9%, and the MHC II antibody flow cytometry result was 46%, proving that BMDCs have been successfully induced.

[0119] Figure 3-6 It can be seen that the cZIF-8 positive rate was 71.8%, the Alum positive rate was 70.4%, the sZIF-8 positive rate was 59%, and the LPS positive control was 74.7%. As can be seen from Figure B, the CD80 and CD86 positive rates of the cZIF-8 adjuvant group were not much different from the LPS positive control group, and the CD80 and CD86 positive rates of the cZIF-8 adjuvant group were significantly higher than those of the Alum group and the sZIF-8 adjuvant group, which can indicate that each adjuvant group can stimulate DC activation after binding with OVA, but the CD80 and CD86 positive rates of the cZIF-8 adjuvant group are more significant, and the up-regulation of the cZIF-8 adjuvant group is more obvious.

[0120] 7. Analysis of cZIF-8@OVA enhancing antigen cross-presentation through lysosome escape

[0121] Poly-L-lysine was used for laser confocal dish washing, and the density of the cultured im-DCs was diluted to 1×10 6 The density of the cultured im-DCs was diluted to 1×10 6 The cZIF-8@FITC OVA, sZIF-8@FITC OVA and Alum@FITC OVA were detected in DCs by laser confocal microscopy. The cZIF-8 adjuvant was mixed with FITC-OVA according to the above steps, incubated with DCs at 37°C, and then operated according to the LysoTracker Red kit instructions. The localization of the different adjuvant-encapsulated antigens and lysosomes was observed by laser excitation at 488nm for green fluorescence and 561nm for red fluorescence.Figure 3-7 As shown.

[0122] Figure 3-7 It can be seen that in cZIF-8@FITC-OVA, the antigen almost completely overlaps with the lysosome, indicating that the antigen is effectively captured and degraded in the lysosome. The Merge image of the cZIF-8 adjuvant group can see the colocalization of the antigen and the lysosome, which means that the cZIF-8 adjuvant can help the lysosomal escape of the antigen, and as a vaccine adjuvant, it can greatly improve the presentation efficiency of the antigen. In the Alum adjuvant group, the antigen overlaps less with the lysosome compared with the cZIF-8 adjuvant group, indicating that the colocalization of the antigen and the lysosome in the Alum adjuvant is not high, and the ability of the antigen to escape from the lysosome is weak. The localization of sZIF-8 adjuvant group and PBS group in DC and the lysosomal escape phenomenon are obviously weaker, and the effect of sZIF-8 adjuvant group in promoting lysosomal escape is not as good as that of cZIF-8 and Alum groups.

[0123] 8. Flow cytometry detection of CD4 + , CD8 + T cell content

[0124] The spleen lymphocytes of the mice at the fifth week after immunization were separated using Ficoll cell separation solution, and the cell surface factors were labeled with mouse FITC-CD3, PE-CD4, and APC-CD8 antibodies and subjected to flow cytometry analysis, and the results are shown in Figure 3-8 .

[0125] Figure 3-8 It can be seen that the proportion of CD4 + T cells in the cZIF-8 adjuvant group and the Alum adjuvant group is significantly higher than that in the sZIF-8 and PBS groups (** p < 0.01), and the proportion of CD8 + T cells in the cZIF-8 adjuvant group and the Alum adjuvant group is almost the same and is also significantly higher than that in the sZIF-8 and PBS groups (**** p < 0.01). From the results, it can be seen that the cZIF-8 adjuvant has the highest content of CD8 + T cells and CD4 + T cells, indicating that it is more effective in activating T cell-mediated immune response. Alum adjuvant also shows good effect, but not as good as cZIF-8. The effect of sZIF-8 is relatively poor, and the effect is also the least obvious compared with cZIF-8 and Alum groups.

[0126] It should be pointed out finally that the above examples are only used to illustrate the technical solutions of the present application but not to limit it; although the present application has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the specific embodiments of the present application can be modified or some technical features can be replaced by equivalent ones without departing from the spirit of the technical solutions of the present application, and all of them should be covered in the technical solution range claimed by the present application.

Claims

1. A cuboid zeolitic imidazolate framework-8 nanoparticle, characterized in that: The nanoparticles comprise elements of carbon, oxygen, zinc, nitrogen and manganese; and are cuboid-shaped ZIF-8 nanoparticles with mesoporous or narrow pore structure, with an aspect ratio of (1-5):1, and the elements of carbon, oxygen, zinc, nitrogen and manganese are uniformly distributed in the cuboid-shaped ZIF-8 nanoparticles; the preparation method of the cuboid-shaped zeolitic imidazolate framework-8 nanoparticles comprises the following steps: dissolving 70-350 parts by mass of a soluble manganese salt in an organic solvent; then adding 150 parts by mass of spherical ZIF-8 nanoparticles, and performing a room temperature oscillation reaction, followed by centrifugal separation; adding the obtained solid material after centrifugal separation to a mixed solution of 2,5-dihydroxyterephthalic acid and an organic solvent, and performing a room temperature oscillation reaction, followed by centrifugal separation and drying, to obtain the cuboid-shaped ZIF-8 nanoparticles.

2. The cuboid-shaped zeolitic imidazolate framework-8 nanoparticles of claim 1, wherein: The first oscillation reaction is performed for 1-3 h; and the second oscillation reaction is performed for 20-30 h.

3. The cuboid-shaped zeolitic imidazolate framework-8 nanoparticles of claim 1, wherein: The soluble manganese salt is manganese chloride tetrahydrate, manganese sulfate or manganese nitrate.

4. The cuboid-shaped zeolitic imidazolate framework-8 nanoparticles of claim 1, wherein: The organic solvent is N,N-dimethylformamide, anhydrous ethanol or methanol.

5. The cuboid-shaped zeolitic imidazolate framework-8 nanoparticle of claim 1, wherein: The preparation method of the spherical ZIF-8 nanoparticles comprises: dissolving a soluble zinc salt in deionized water to obtain solution A; dissolving 2-methylimidazole in deionized water to obtain solution B; mixing and reacting solution A and solution B, followed by centrifugal separation, washing and drying, to obtain the spherical ZIF-8 nanoparticles.

6. The cuboid zeolitic imidazolate framework-8 nanoparticle of claim 5, wherein: The molar ratio of the soluble zinc salt to 2-methylimidazole is 1:(2-4).

7. The cuboid zeolitic imidazolate framework-8 nanoparticle of claim 5, wherein: The soluble zinc salt is zinc acetate dihydrate, zinc nitrate hexahydrate, zinc chloride or zinc sulfate; and the deionized water has a resistivity of no less than 18.2 MΩ / cm.

8. Use of the cuboid-shaped zeolitic imidazolate framework-8 nanoparticles of claim 1 in the preparation of an adjuvant.

9. Use according to claim 8, characterized in that: The adjuvant is used in the preparation of a prophylactic biological product or an immunotherapeutic drug.

Citation Information

Patent Citations

  • Metal organic framework material with hollow structure and preparation method thereof, solid-phase micro-extractant containing metal organic framework material and preparation method and application of solid-phase micro-extractant

    CN119192599A

  • Preparation method and application of MOF-74 with hollow structure

    CN119219937A